(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Slides:



Advertisements
Similar presentations
Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis
Advertisements

Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
(A) Lequesne index and quadriceps strength of patients with knee OA
Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.
Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
Changes in evaluation indicators from baseline to 12 weeks per visit.
Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.
Percentage of patients achieving EULAR response
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.
Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.
Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.
Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.
Clinical response in patients with early and established RA at month 24. *p
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.
Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.
Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.
Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.
Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
Achilles tendon tear. Achilles tendon tear. (A) Longitudinal and (B) transverse images of the calf: at the middle third of the left Achilles tendon there.
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
Heterogeneity of TCRβ repertoire in autoimmune diseases.
Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI
Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.
 Line graph showing mean (SEM) values for ankle pain on activity for intermittent and standard groups at baseline and week 1, 2, 3, 4, and 6 after injury.
Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free.
Increased numbers of LDGs in association with disease activity and low complement levels in patients with SLE. Numbers of LDGs were determined by flow.
 Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.
(A–F) Changes of B-cell numbers and B-cell related biomarkers.
Fluoroscopic image of the suprascapular nerve block injection.
Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.
Mean disease activity score based on a 28-joint count (DAS28 (ESR)) (A), Clinical Disease Activity Index (CDAI) score (B) and Simplified Disease Activity.
Multivariable model of adjusted
(A) Sensitivity and specificity values seen in the 827 patients with HSP versus the other forms of childhood vasculitides (c-PAN 150, c-WG 60, c-TA 87).
Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.
Status of tapering in the first year of follow-up.
 Ultrasonographic picture of second metatarsophalangeal joint with synovitis (panel A) and without synovitis (panel B). a, metatarsal head; b, base of.
ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.
Dual-energy CT images. Dual-energy CT images. Arrows indicate MSU deposition (MSU deposits colour coded in green). (A) Subject accuracy study with acute.
Seven weeks after presentation: scattered posterior pole intra-retinal haemorrhages and cotton wool spots; right eye (A) and left eye (B). Seven weeks.
Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.
Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),
Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.
Patient disposition. *n=1 patient took prohibited concomitant medication due to an adverse event and was discontinued from the study. Patient disposition.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid.
Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.
The right hand of the same patient as in figure 1, photographed from the ulnar side, showing dorsolateral nodes in profile on the index and ring fingers,
SMD (95% CI) for outcomes at 12 weeks
(A) A barium follow-through showing a dilated oesophagus with markedly dilated loops of the small bowel; (B) abdominal computed tomography showing dilated,
(A) Short Health Scale (SHS) dimension scores (left) and Psychological General Well-Being Index (PGWBI) global scores (right) for the open-label phase.
Baker’s cyst (photomontage).
Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.
Presentation transcript:

(A) JIA-ACR30/50/70/90 response rates by visit in part 1. (A) JIA-ACR30/50/70/90 response rates by visit in part 1. (B) Line plot of JIA-ACR core components by week in part 1. (C) JIA-ACR30/50/70/90 improvement by treatment group at the end of part 1 at week 16. (D) Time to JIA-ACR30 flare after randomisation in the withdrawal phase (part 2); part 1 treatment is indicated in parentheses. For JIA-ACR responses (A, C), n=188. For JIA-ACR core components (B), n=182–187 for number of joints with active arthritis and number of joints with limitation of movement; n=178–184 for assessment of patient overall well-being; n=181–187 for physician global assessment of disease activity; n=182–184 for CHAQ-DI; and n=182–188 for ESR. For time to JIA-ACR30 flare (D), n=number of patients remaining in the study at each time point. aLog-rank test adjusted for stratification factors applied at randomisation in part 1 was a predefined, exploratory analysis. HR, 0.36; 95% CI 0.19 to 0.67. CHAQ-DI, Childhood Health Assessment Questionnaire-Disability Index; ESR, erythrocyte sedimentation rate; JIA-ACR, juvenile idiopathic arthritis-American College of Rheumatology; VAS, visual analogue scale. Hermine I Brunner et al. Ann Rheum Dis 2015;74:1110-1117 ©2015 by BMJ Publishing Group Ltd and European League Against Rheumatism